Radiation treatment for patients with intermediate-risk prostate cancer

David E. Greene; Jyoti S. Mayadev; Richard K Valicenti

doi:10.1177/1756287212442977

Radiation treatment for patients with intermediate-risk prostate cancer

David E. Greene, Jyoti S. Mayadev, Richard K Valicenti

Radiation Oncology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Around 70% of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.

Original language	English (US)
Pages (from-to)	113-124
Number of pages	12
Journal	Therapeutic Advances in Urology
Volume	4
Issue number	3
DOIs	https://doi.org/10.1177/1756287212442977
State	Published - Jun 2012

Keywords

androgen deprivation
brachytherapy
dose escalation
external beam
intermediate risk
outcomes
prostate cancer
radiation
review

ASJC Scopus subject areas

Urology

Access to Document

10.1177/1756287212442977

Fingerprint Dive into the research topics of 'Radiation treatment for patients with intermediate-risk prostate cancer'. Together they form a unique fingerprint.

Cite this

@article{076124c6ae154e78b3ac58f01625708e,

title = "Radiation treatment for patients with intermediate-risk prostate cancer",

abstract = "Around 70% of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.",

keywords = "androgen deprivation, brachytherapy, dose escalation, external beam, intermediate risk, outcomes, prostate cancer, radiation, review",

author = "Greene, {David E.} and Mayadev, {Jyoti S.} and Valicenti, {Richard K}",

year = "2012",

month = jun,

doi = "10.1177/1756287212442977",

language = "English (US)",

volume = "4",

pages = "113--124",

journal = "Therapeutic Advances in Urology",

issn = "1756-2872",

publisher = "SAGE Publications Inc.",

number = "3",

}

TY - JOUR

T1 - Radiation treatment for patients with intermediate-risk prostate cancer

AU - Greene, David E.

AU - Mayadev, Jyoti S.

AU - Valicenti, Richard K

PY - 2012/6

Y1 - 2012/6

N2 - Around 70% of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.

AB - Around 70% of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.

KW - androgen deprivation

KW - brachytherapy

KW - dose escalation

KW - external beam

KW - intermediate risk

KW - outcomes

KW - prostate cancer

KW - radiation

KW - review

UR - http://www.scopus.com/inward/record.url?scp=84861864345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861864345&partnerID=8YFLogxK

U2 - 10.1177/1756287212442977

DO - 10.1177/1756287212442977

M3 - Article

C2 - 22654963

AN - SCOPUS:84861864345

VL - 4

SP - 113

EP - 124

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

IS - 3

ER -